The Framework for Policy Decision on the RTS,S/AS01 malaria vaccine: the use of emerging data to inform global policy on the first malaria vaccine

The World Health Organization (WHO)-coordinated Malaria Vaccine Implementation Programme (MVIP) supported pilot introductions of the RTS,S/AS01 malaria vaccine by the ministries of health through the childhood immunization programmes in Ghana, Kenya and Malawi from 2019 through 2023. The MVIP was designed to consolidate the vaccine’s safety, and to document the feasibility of implementation and impact in routine use. A 46-month period of surveillance was estimated to be sufficient to measure these outcomes, and to assess an impact on mortality. Before vaccine introduction in the three countries, a Framework for Policy Decision (Framework) [1] was developed to guide and build expert consensus around how emerging data from the pilot evaluations would be used to inform WHO policy recommendations. The Framework established a hierarchy of MVIP objectives, with safety being of highest importance, followed by impact, and lastly feasibility. The Framework outlined a stepwise policy process that would support a recommendation for use as soon as vaccine safety was established and there was evidence of a trend in reducing severe malaria or mortality. Early evaluation of these milestones would enable planning for scale-up by the manufacturer, accelerate financing and procurement of the vaccine and minimize the delay in the introduction of a potentially life-saving vaccine to children at risk. The evaluation would continue beyond any initial recommendation, which would be based primarily on data from the first 3 of 4 vaccine doses, to measure impact definitively and assess the added value of the fourth vaccine dose. Any required modification to the initial recommendations could be made dependent on the final results. By following this stepwise process, the Framework succeeded in assuring safety while enabling faster vaccine introduction for children at risk—at least 2 years earlier than would have been the case had a policy recommendation been delayed until the completion of the MVIP. The Framework and its approach serve as a model for future decision-making around potentially impactful health interventions when outstanding public health questions require further evaluation prior to a broad recommendation for use.

Authors

Institutions

Publication Details

Journal
Malaria Journal
Published
2026-10-06
DOI
https://doi.org/10.1186/s12936-026-06160-z
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Framework for Policy Decision on the RTS,S/AS01 malaria vaccine: the use of emerging data to inform global policy on the first malaria vaccine

W. Scott Gordon, Fred Were, Kim Mulholland, Kamini Mendis et al.
Malaria Journal
Malaria Research and Control
article

The Framework for Policy Decision on the RTS,S/AS01 malaria vaccine: the use of emerging data to inform global policy on the first malaria vaccine

W. Scott Gordon, Fred Were, Kim Mulholland, Kamini Mendis, Umberto D’Alessandro, Terry M. Nolan, Ryan R. Thompson, Peter G. Smith, Jenny Anne Walldorf, David M. Schellenberg, Katherine L. O'Flynn O'Brien, Paul J. Milligan, Gabriel Carrasquilla, Quique Bassat, Rebecca Mary Casey, Melissa A. Penny, Eusébio Macete, Mary J. Hamel, Eliane Pellaux-Furrer, Laurence Slutsker, Pedro L. Alonso, Cynthia Bergstrom
article en

Abstract

The World Health Organization (WHO)-coordinated Malaria Vaccine Implementation Programme (MVIP) supported pilot introductions of the RTS,S/AS01 malaria vaccine by the ministries of health through the childhood immunization programmes in Ghana, Kenya and Malawi from 2019 through 2023. The MVIP was designed to consolidate the vaccine’s safety, and to document the feasibility of implementation and impact in routine use. A 46-month period of surveillance was estimated to be sufficient to measure these outcomes, and to assess an impact on mortality. Before vaccine introduction in the three countries, a Framework for Policy Decision (Framework) [1] was developed to guide and build expert consensus around how emerging data from the pilot evaluations would be used to inform WHO policy recommendations. The Framework established a hierarchy of MVIP objectives, with safety being of highest importance, followed by impact, and lastly feasibility. The Framework outlined a stepwise policy process that would support a recommendation for use as soon as vaccine safety was established and there was evidence of a trend in reducing severe malaria or mortality. Early evaluation of these milestones would enable planning for scale-up by the manufacturer, accelerate financing and procurement of the vaccine and minimize the delay in the introduction of a potentially life-saving vaccine to children at risk. The evaluation would continue beyond any initial recommendation, which would be based primarily on data from the first 3 of 4 vaccine doses, to measure impact definitively and assess the added value of the fourth vaccine dose. Any required modification to the initial recommendations could be made dependent on the final results. By following this stepwise process, the Framework succeeded in assuring safety while enabling faster vaccine introduction for children at risk—at least 2 years earlier than would have been the case had a policy recommendation been delayed until the completion of the MVIP. The Framework and its approach serve as a model for future decision-making around potentially impactful health interventions when outstanding public health questions require further evaluation prior to a broad recommendation for use.

Malaria Journal
University of Nairobi (KE), Centers for Disease Control and Prevention (US), Gavi (CH), Harvard University (US), The University of Melbourne (AU), The Kids Research Institute Australia (AU), The University of Western Australia (AU), Lúrio University (MZ), London School of Hygiene & Tropical Medicine (GB), World Health Organization (CH), MRC Unit the Gambia (GM), Manhiça Health Research Centre (MZ), Kenya Paediatric Research Consortium (KE), Barcelona Institute for Global Health (ES), Universitat de Barcelona (ES), University of Colombo (LK)
Openalex Percentile: Top 9%
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.